BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Bleomycin
,
rs2300478
,
MDM2
,
cell-cell adhesion
,
Arthritis
,
Lung
,
Personalized medicine
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
antigens cd274
Summary
General Info
Curated Studies
Most Correlated Studies
CD8+ T cells from OT-1 mice after exposure to PD-L1
Colorectal cancer (HT29 & HCT116) and melanoma PES43 cells treated with Nivolumab, sPD-L1 or both
Plasmacytoid dendritic cell stimulated with influenza virus and sorted for PD-L1+ CD80+
Tumor-specific Th1 cells activated in vivo
Explore Curated Studies Results
Literature
Most Relevant Literature
Expression and Prognostic Significance of PD-L1 and NY-ESO1 in Gallbladder Carcinoma.
Evaluating regulatory consistency for international anti-PD-(L)1 clinical trials.
Tumor-immune metaphenotypes orchestrate an evolutionary bottleneck that promotes metabolic transform…
Research progress in the regulation of tumor cell PD-L1 expression by N6-methyladenosine modificatio…
Regeneration and rejuvenation of skin by a topical YAP activator.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Neurofilament Light Chain ,Chitinase-3 Like-1 Proteins and Plasmacytoid Dendritic Cells in Multiple …
Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GU…
GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study
Immune Responsiveness and Outcome After Aortic Valve Surgery (Measure)
PD-1 Inhibitors Plus Chemoradiotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: an Open…
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ